Cambridge Healthtech Institute’s Inaugural

Targeting Innate Immunity

Differentiating Friends from Foes

September 24 - 25, 2019


As our knowledge of the complex innate immune system increases, new opportunities to develop novel treatments by utilizing the innate immune cells are significantly enhanced. Cambridge Healthtech Institute's Inaugural Targeting Innate Immunity Congress will convene all the thought leaders including industry experts, academic researchers and clinicians to deepen our understanding of the innate immunity and how to harness their power for effective immunotherapies. This 2-day congress focuses on the current landscape and novel advances in the field of innate immunotherapy such as natural killer cells, macrophages and dendritic cells. Be part of the conversation on mechanisms of action of innate cells, effective modulating strategies, the impact of tumor microenvironment and many more.

Preliminary Agenda

ENGINEERING STRATEGIES FOR NK, NKT AND GAMMA DELTA

Her2-CAR Engineered Natural Killer Cell Line as Off-the-Shelf Adoptive Immunotherapy in Solid Cancer

Torsten Tonn, MD, PhD, Group Leader, Research Laboratory Experimental Transfusion Medicine; Professor, Transfusion Medicine, Medical Faculty Carl-Gustav-Carus, Technische Universität Dresden, Germany

Translation of Pluripotent Cell-Derived Engineered NK Cells as a Cornerstone Approach for Off-The-Shelf Cancer Immunotherapy

Bob Valamehr, PhD, MBA, Chief Development Officer, Fate Therapeutics, Inc.

Advances in Tri-Specific Killer Engager (TriKE) Molecules for NK Cell Antigen-Specific Recognition of Tumor Cells in High Risk MDS and Refractory AML Settings

Martin Felices, PhD, Assistant Professor of Medicine, Co-Director, Translational Therapy Laboratory, Hematology, Oncology and Transplantation, University of Minnesota

Novel Innate Killer Cell Platform for Empowering Cell Therapies for Cancers

Mark A. Exley, PhD, Vice President, Cellular Immunology, AgenTus Therapeutics, Inc.

Bispecific Gamma Delta T Cell Engagers for Cancer Immunotherapy

Hans J. van der Vliet, Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands

REPROGRAMMING TUMOR mICROENVIRONMENT: tARGETING MYELOID CELLS, ILCS, AND MACROPHAGES

A Designer Self-Assembled Supramolecule Amplifies Macrophage Immune Responses Against Aggressive Cancer

Shiladitya Sengupta, PhD, Principle Investigator, Engineering in Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology

Reprogramming Immune Cells in the Tumor Microenvironment to Treat Pancreatic Cancer

Scott A. Gerber, PhD, Assistant Professor, Co-Director, Center for Tumor Immunology Research, Surgery, Microbiology, Immunology, Radiation Oncology, University of Rochester Medical Center

Contribution to Tumor Angiogenesis from Innate Immune Cells within the Tumor Microenvironment: Implications for Immunotherapy

Adriana Albini, PhD, Scientific Director, Fondazione MultiMedica Onlus

Innate Lymphoid Cell (ILC) Functional Manipulation for Innovative Cancer Immunotherapy

Camilla Jandus, MD, PhD, Principal Investigator, Assistant Professor, Oncology, University of Lausanne, Switzerland

ADVANCES IN CLINICAL TRIALS FOR INNATE CELL THERAPIES

Off-the-Shelf NK Cells for Malignancies and Infections

Sumithira Vasu, MBBS, Assistant Professor, The Ohio State University Medical Center

Memory-Like NK Cells for Relapsed Myeloid Malignancies

Rizwan Romee, MD, Member Faculty and Director, Haploidentical Donor Transplant Program, Oncology/ BMT and Leukemia Program, Dana Farber Cancer Institute, Harvard Medical School

Off-the-Shelf, Engineered NK Cell Lines for Patient-Specific Cancer Treatment

Hans Klingemann, MD, PhD, Vice President, Research & Development, NantKwest, Inc.

The Role of Natural Killer Cells in Cancer Immunotherapy and Oncolytic Virotherapy

Jianhua Yu, PhD, Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope




For more details on the conference, please contact:
Emily Le
Conference Producer
Cambridge Healthtech Institute
Phone: 781-247-1812
Email: ele@healthtech.com

For partnering and sponsorship information, please contact:
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-1340
Email: ashleyparsons@cambridgeinnovationinstitute.com